Silence Therapeutics (SLN) stock was initiated by Goldman Sachs with a Sell recommendation citing potential funding ...

Fintel reports that on February 11, 2025, Goldman Sachs initiated coverage of Silence Therapeutics plc - Depositary Receipt ( ...

Goldman Sachs initiated coverage of Silence Therapeutics (SLN) with a Sell rating and $6 price target The company is developing siRNA ...

Goldman Sachs analyst Richard Law initiated coverage of Silence Therapeutics (SLN) with a Sell rating and $6 price target Maximize Your ...

Goldman Sachs initiated coverage on Silence Therapeutics (NASDAQ:SLN), currently trading at $4.92 with a market cap of $232.3 million, with a Sell rating and a price target of $6.00. According to ...

Silence Therapeutics plc (NASDAQ:SLN – Get Free Report) has received an average recommendation of “Buy” from the six ratings ...

Danielle Rasooly, PhD, of the Division of Aging at Brigham and Women’s Hospital, is the co-corresponding author of a paper published in Nature Cardiovascular Research, “Large-scale multi-omics ...

How would you summarize your study for a lay audience?Heart failure remains a substantial burden for patients due to its high ...

UK biotech e-therapeutics has a new CEO, with executive chairman and former Silence Therapeutics chief Ali Mortazavi chosen to spearhead the next stage in the company’s development into gene ...

In a new study just published in the European Heart Journal, researchers from Herlev and Gentofte Hospital quantify for the first time how life expectancy and cardiovascular disease in people ...

Explore latest progress in siRNA chemistry to increase activity, stability, specificity & potential off target effects to improve cellular targeting with insights from Silence Therapeutics & Aro ...